Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Putative tumour-suppressor gene DAB2is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma

Authors: Joanna H Tong, David C Ng, Shuk L Chau, Ken K So, Patrick P Leung, Tin L Lee, Raymond W Lung, Michael W Chan, Anthony W Chan, Kwok W Lo, Ka F To

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Human Disabled-2 (DAB2), is a multi-function signalling molecule that it is frequently down-regulated in human cancers. We aimed to investigate the possible tumour suppressor effect of DAB2 in nasopharyngeal carcinoma (NPC).

Methods

We studied the expression of DAB2 in NPC cell lines, xenografts and primary tumour samples. The status of promoter methylation was assessed by methylation specific PCR and bisulfite sequencing. The functional role of DAB2 in NPC was investigated by re-introducing DAB2 expression into NPC cell line C666-1.

Results

Decrease or absent of DAB2 transcript was observed in NPC cell lines and xenografts. Loss of DAB2 protein expression was seen in 72% (33/46) of primary NPC as demonstrated by immunohistochemistry. Aberrant DAB2 promoter methylation was detected in 65.2% (30/46) of primary NPC samples by methylation specific PCR. Treatment of the DAB2 negative NPC cell line C666-1 with 5-aza-2'-deoxycytidine resulted in restoration of DAB2 expression in a dose-dependent manner. Overexpression of DAB2 in NPC cell line C666-1 resulted in reduced growth rate and 35% reduction in anchorage-dependent colony formation, and inhibition of serum-induced c-Fos expression compared to vector-transfected controls. Over expression of DAB2 resulted in alterations of multiple pathways as demonstrated by expression profiling and functional network analysis, which confirmed the role of DAB2 as an adaptor molecule involved in multiple receptor-mediated signalling pathways.

Conclusions

We report the frequent down regulation of DAB2 in NPC and the promoter hypermethylation contributes to the loss of expression of DAB2. This is the first study demonstrating frequent DAB2 promoter hypermethylation in human cancer. Our functional studies support the putative tumour suppressor effect of DAB2 in NPC cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lo KW, To KF, Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell. 2004, 5: 423-428. 10.1016/S1535-6108(04)00119-9.CrossRefPubMed Lo KW, To KF, Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell. 2004, 5: 423-428. 10.1016/S1535-6108(04)00119-9.CrossRefPubMed
2.
go back to reference Xu XX, Yi T, Tang B, Lambeth JD: Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene. 1998, 16: 1561-1569. 10.1038/sj.onc.1201678.CrossRefPubMed Xu XX, Yi T, Tang B, Lambeth JD: Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene. 1998, 16: 1561-1569. 10.1038/sj.onc.1201678.CrossRefPubMed
3.
go back to reference Zhou J, Hsieh JT: The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. J Biol Chem. 2001, 276: 27793-27798. 10.1074/jbc.M102803200.CrossRefPubMed Zhou J, Hsieh JT: The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. J Biol Chem. 2001, 276: 27793-27798. 10.1074/jbc.M102803200.CrossRefPubMed
4.
go back to reference Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, Cooper JA, Luzio JP, Buss F: Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton. Traffic. 2002, 3: 331-341. 10.1034/j.1600-0854.2002.30503.x.CrossRefPubMed Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, Cooper JA, Luzio JP, Buss F: Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton. Traffic. 2002, 3: 331-341. 10.1034/j.1600-0854.2002.30503.x.CrossRefPubMed
5.
go back to reference Morris SM, Cooper JA: Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2. Traffic. 2001, 2: 111-123. 10.1034/j.1600-0854.2001.020206.x.CrossRefPubMed Morris SM, Cooper JA: Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2. Traffic. 2001, 2: 111-123. 10.1034/j.1600-0854.2001.020206.x.CrossRefPubMed
6.
go back to reference Hocevar BA, Prunier C, Howe PH: Disabled-2 (Dab2) mediates transforming growth factor beta (TGFbeta)-stimulated fibronectin synthesis through TGFbeta-activated kinase 1 and activation of the JNK pathway. J Biol Chem. 2005, 280: 25920-25927. 10.1074/jbc.M501150200.CrossRefPubMed Hocevar BA, Prunier C, Howe PH: Disabled-2 (Dab2) mediates transforming growth factor beta (TGFbeta)-stimulated fibronectin synthesis through TGFbeta-activated kinase 1 and activation of the JNK pathway. J Biol Chem. 2005, 280: 25920-25927. 10.1074/jbc.M501150200.CrossRefPubMed
7.
go back to reference Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT: The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem. 2002, 277: 12622-12631. 10.1074/jbc.M110568200.CrossRefPubMed Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT: The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem. 2002, 277: 12622-12631. 10.1074/jbc.M110568200.CrossRefPubMed
8.
go back to reference Prunier C, Howe PH: Disable-2 (Dab-2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT). J Biol Chem. 2005, 280: 17540-17548. 10.1074/jbc.M500974200.CrossRefPubMed Prunier C, Howe PH: Disable-2 (Dab-2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT). J Biol Chem. 2005, 280: 17540-17548. 10.1074/jbc.M500974200.CrossRefPubMed
9.
go back to reference Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, Howe PH: Regulation of the Wnt signaling pathway by disabled-2 (Dab2). Embo J. 2003, 22: 3084-3094. 10.1093/emboj/cdg286.CrossRefPubMedPubMedCentral Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, Howe PH: Regulation of the Wnt signaling pathway by disabled-2 (Dab2). Embo J. 2003, 22: 3084-3094. 10.1093/emboj/cdg286.CrossRefPubMedPubMedCentral
10.
go back to reference Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS: DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene. 1998, 16: 2381-2387. 10.1038/sj.onc.1201769.CrossRefPubMed Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS: DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene. 1998, 16: 2381-2387. 10.1038/sj.onc.1201769.CrossRefPubMed
11.
go back to reference Bagadi SA, Prasad CP, Srivastava A, Prashad R, Gupta SD, Ralhan R: Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Res Treat. 2007, 104: 277-286. 10.1007/s10549-006-9422-6.CrossRefPubMed Bagadi SA, Prasad CP, Srivastava A, Prashad R, Gupta SD, Ralhan R: Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Res Treat. 2007, 104: 277-286. 10.1007/s10549-006-9422-6.CrossRefPubMed
12.
go back to reference Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX: Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene. 1999, 18: 3104-3113. 10.1038/sj.onc.1202649.CrossRefPubMed Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX: Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene. 1999, 18: 3104-3113. 10.1038/sj.onc.1202649.CrossRefPubMed
13.
go back to reference Tseng CP, Ely BD, Li Y, Pong RC, Hsieh JT: Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology. 1998, 139: 3542-3553. 10.1210/en.139.8.3542.PubMed Tseng CP, Ely BD, Li Y, Pong RC, Hsieh JT: Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology. 1998, 139: 3542-3553. 10.1210/en.139.8.3542.PubMed
14.
go back to reference Zhou J, Scholes J, Hsieh JT: Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem. 2003, 278: 6936-6941. 10.1074/jbc.M210628200.CrossRefPubMed Zhou J, Scholes J, Hsieh JT: Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem. 2003, 278: 6936-6941. 10.1074/jbc.M210628200.CrossRefPubMed
15.
go back to reference Anupam K, Tusharkant C, Gupta SD, Ranju R: Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J Gastroenterol. 2006, 12: 6041-6045.CrossRefPubMedPubMedCentral Anupam K, Tusharkant C, Gupta SD, Ranju R: Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J Gastroenterol. 2006, 12: 6041-6045.CrossRefPubMedPubMedCentral
16.
go back to reference Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT: Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res. 2007, 13: 4400-4406. 10.1158/1078-0432.CCR-07-0287.CrossRefPubMed Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT: Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res. 2007, 13: 4400-4406. 10.1158/1078-0432.CCR-07-0287.CrossRefPubMed
17.
go back to reference Kleeff J, Huang Y, Mok SC, Zimmermann A, Friess H, Buchler MW: Down-regulation of DOC-2 in colorectal cancer points to its roles as a tumor suppressor in this malignancy. Dis Colon Rectum. 2002, 45: 1242-1248. 10.1007/s10350-004-6399-2.CrossRefPubMed Kleeff J, Huang Y, Mok SC, Zimmermann A, Friess H, Buchler MW: Down-regulation of DOC-2 in colorectal cancer points to its roles as a tumor suppressor in this malignancy. Dis Colon Rectum. 2002, 45: 1242-1248. 10.1007/s10350-004-6399-2.CrossRefPubMed
18.
go back to reference Fulop V, Colitti CV, Genest D, Berkowitz RS, Yiu GK, Ng SW, Szepesi J, Mok SC: DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene. 1998, 17: 419-424. 10.1038/sj.onc.1201955.CrossRefPubMed Fulop V, Colitti CV, Genest D, Berkowitz RS, Yiu GK, Ng SW, Szepesi J, Mok SC: DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene. 1998, 17: 419-424. 10.1038/sj.onc.1201955.CrossRefPubMed
19.
go back to reference Zhou J, Hernandez G, Tu SW, Scholes J, Chen H, Tseng CP, Hsieh JT: Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor. Cancer Res. 2005, 65: 6089-6096. 10.1158/0008-5472.CAN-04-3672.CrossRefPubMed Zhou J, Hernandez G, Tu SW, Scholes J, Chen H, Tseng CP, Hsieh JT: Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor. Cancer Res. 2005, 65: 6089-6096. 10.1158/0008-5472.CAN-04-3672.CrossRefPubMed
20.
go back to reference Chow LS, Lo KW, Kwong J, To KF, Tsang KS, Lam CW, Dammann R, Huang DP: RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer. 2004, 109: 839-847. 10.1002/ijc.20079.CrossRefPubMed Chow LS, Lo KW, Kwong J, To KF, Tsang KS, Lam CW, Dammann R, Huang DP: RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer. 2004, 109: 839-847. 10.1002/ijc.20079.CrossRefPubMed
21.
go back to reference Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z, Wong N, Yuen PW, Lo AK, Wong YC, Huang DP: Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta. 2002, 1590: 150-158. 10.1016/S0167-4889(02)00208-2.CrossRefPubMed Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z, Wong N, Yuen PW, Lo AK, Wong YC, Huang DP: Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta. 2002, 1590: 150-158. 10.1016/S0167-4889(02)00208-2.CrossRefPubMed
22.
go back to reference Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, et al: Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology. 2009, 136: 640-651. 10.1053/j.gastro.2008.10.050. e641.CrossRefPubMed Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, et al: Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology. 2009, 136: 640-651. 10.1053/j.gastro.2008.10.050. e641.CrossRefPubMed
23.
go back to reference Tong JH, Tsang RK, Lo KW, Woo JK, Kwong J, Chan MW, Chang AR, van Hasselt CA, Huang DP, To KF: Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. Clin Cancer Res. 2002, 8: 2612-2619.PubMed Tong JH, Tsang RK, Lo KW, Woo JK, Kwong J, Chan MW, Chang AR, van Hasselt CA, Huang DP, To KF: Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. Clin Cancer Res. 2002, 8: 2612-2619.PubMed
24.
go back to reference Sheng Z, He J, Tuppen JA, Sun W, Fazili Z, Smith ER, Dong FB, Xu XX: Structure, sequence, and promoter analysis of human disabled-2 gene (DAB2). Genomics. 2000, 70: 381-386. 10.1006/geno.2000.6383.CrossRefPubMed Sheng Z, He J, Tuppen JA, Sun W, Fazili Z, Smith ER, Dong FB, Xu XX: Structure, sequence, and promoter analysis of human disabled-2 gene (DAB2). Genomics. 2000, 70: 381-386. 10.1006/geno.2000.6383.CrossRefPubMed
25.
go back to reference Zhoul J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT: The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res. 2005, 65: 9906-9913. 10.1158/0008-5472.CAN-05-1481.CrossRefPubMed Zhoul J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT: The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res. 2005, 65: 9906-9913. 10.1158/0008-5472.CAN-05-1481.CrossRefPubMed
26.
go back to reference Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
27.
go back to reference Xu XX, Yang W, Jackowski S, Rock CO: Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product. J Biol Chem. 1995, 270: 14184-14191. 10.1074/jbc.270.23.14184.CrossRefPubMed Xu XX, Yang W, Jackowski S, Rock CO: Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product. J Biol Chem. 1995, 270: 14184-14191. 10.1074/jbc.270.23.14184.CrossRefPubMed
28.
go back to reference He J, Smith ER, Xu XX: Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation. J Biol Chem. 2001, 276: 26814-26818. 10.1074/jbc.M101820200.CrossRefPubMed He J, Smith ER, Xu XX: Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation. J Biol Chem. 2001, 276: 26814-26818. 10.1074/jbc.M101820200.CrossRefPubMed
29.
go back to reference Wong N, Hui AB, Fan B, Lo KW, Pang E, Leung SF, Huang DP, Johnson PJ: Molecular cytogenetic characterization of nasopharyngeal carcinoma cell lines and xenografts by comparative genomic hybridization and spectral karyotyping. Cancer Genet Cytogenet. 2003, 140: 124-132. 10.1016/S0165-4608(02)00657-X.CrossRefPubMed Wong N, Hui AB, Fan B, Lo KW, Pang E, Leung SF, Huang DP, Johnson PJ: Molecular cytogenetic characterization of nasopharyngeal carcinoma cell lines and xenografts by comparative genomic hybridization and spectral karyotyping. Cancer Genet Cytogenet. 2003, 140: 124-132. 10.1016/S0165-4608(02)00657-X.CrossRefPubMed
30.
go back to reference Hui AB, Lo KW, Leung SF, Teo P, Fung MK, To KF, Wong N, Choi PH, Lee JC, Huang DP: Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer. 1999, 82: 498-503. 10.1002/(SICI)1097-0215(19990812)82:4<498::AID-IJC5>3.0.CO;2-S.CrossRefPubMed Hui AB, Lo KW, Leung SF, Teo P, Fung MK, To KF, Wong N, Choi PH, Lee JC, Huang DP: Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer. 1999, 82: 498-503. 10.1002/(SICI)1097-0215(19990812)82:4<498::AID-IJC5>3.0.CO;2-S.CrossRefPubMed
31.
go back to reference Lo KW, Teo PM, Hui AB, To KF, Tsang YS, Chan SY, Mak KF, Lee JC, Huang DP: High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res. 2000, 60: 3348-3353.PubMed Lo KW, Teo PM, Hui AB, To KF, Tsang YS, Chan SY, Mak KF, Lee JC, Huang DP: High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res. 2000, 60: 3348-3353.PubMed
32.
go back to reference Akiyama Y, Watkins N, Suzuki H, Jair KW, van Engeland M, Esteller M, Sakai H, Ren CY, Yuasa Y, Herman JG, Baylin SB: GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol. 2003, 23: 8429-8439. 10.1128/MCB.23.23.8429-8439.2003.CrossRefPubMedPubMedCentral Akiyama Y, Watkins N, Suzuki H, Jair KW, van Engeland M, Esteller M, Sakai H, Ren CY, Yuasa Y, Herman JG, Baylin SB: GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol. 2003, 23: 8429-8439. 10.1128/MCB.23.23.8429-8439.2003.CrossRefPubMedPubMedCentral
33.
go back to reference Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ, Huang DP: High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 2001, 61: 3877-3881.PubMed Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ, Huang DP: High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 2001, 61: 3877-3881.PubMed
34.
go back to reference Hui AB, Lo KW, Kwong J, Lam EC, Chan SY, Chow LS, Chan AS, Teo PM, Huang DP: Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog. 2003, 38: 170-178. 10.1002/mc.10156.CrossRefPubMed Hui AB, Lo KW, Kwong J, Lam EC, Chan SY, Chow LS, Chan AS, Teo PM, Huang DP: Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog. 2003, 38: 170-178. 10.1002/mc.10156.CrossRefPubMed
35.
go back to reference Kwong J, Lo KW, Chow LS, Chan FL, To KF, Huang DP: Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma. Int J Cancer. 2005, 113: 386-392. 10.1002/ijc.20593.CrossRefPubMed Kwong J, Lo KW, Chow LS, Chan FL, To KF, Huang DP: Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma. Int J Cancer. 2005, 113: 386-392. 10.1002/ijc.20593.CrossRefPubMed
36.
go back to reference Kwong J, Chow LS, Wong AY, Hung WK, Chung GT, To KF, Chan FL, Daigo Y, Nakamura Y, Huang DP, Lo KW: Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma. Genes Chromosomes Cancer. 2007, 46: 171-180. 10.1002/gcc.20398.CrossRefPubMed Kwong J, Chow LS, Wong AY, Hung WK, Chung GT, To KF, Chan FL, Daigo Y, Nakamura Y, Huang DP, Lo KW: Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma. Genes Chromosomes Cancer. 2007, 46: 171-180. 10.1002/gcc.20398.CrossRefPubMed
37.
go back to reference Fukayama M, Hino R, Uozaki H: Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci. 2008, 99: 1726-1733. 10.1111/j.1349-7006.2008.00888.x.CrossRefPubMed Fukayama M, Hino R, Uozaki H: Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci. 2008, 99: 1726-1733. 10.1111/j.1349-7006.2008.00888.x.CrossRefPubMed
38.
go back to reference Tsai CL, Li HP, Lu YJ, Hsueh C, Liang Y, Chen CL, Tsao SW, Tse KP, Yu JS, Chang YS: Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer Res. 2006, 66: 11668-11676. 10.1158/0008-5472.CAN-06-2194.CrossRefPubMed Tsai CL, Li HP, Lu YJ, Hsueh C, Liang Y, Chen CL, Tsao SW, Tse KP, Yu JS, Chang YS: Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer Res. 2006, 66: 11668-11676. 10.1158/0008-5472.CAN-06-2194.CrossRefPubMed
39.
go back to reference Yang DH, Smith ER, Cai KQ, Xu XX: C-Fos elimination compensates for disabled-2 requirement in mouse extraembryonic endoderm development. Dev Dyn. 2009, 238: 514-523. 10.1002/dvdy.21856.CrossRefPubMedPubMedCentral Yang DH, Smith ER, Cai KQ, Xu XX: C-Fos elimination compensates for disabled-2 requirement in mouse extraembryonic endoderm development. Dev Dyn. 2009, 238: 514-523. 10.1002/dvdy.21856.CrossRefPubMedPubMedCentral
40.
go back to reference Jiang Y, Prunier C, Howe PH: The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin. Oncogene. 2008, 27: 1865-1875. 10.1038/sj.onc.1210829.CrossRefPubMed Jiang Y, Prunier C, Howe PH: The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin. Oncogene. 2008, 27: 1865-1875. 10.1038/sj.onc.1210829.CrossRefPubMed
41.
go back to reference Chou J, Lin YC, Kim J, You L, Xu Z, He B, Jablons DM: Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck. 2008, 30: 946-963. 10.1002/hed.20833.CrossRefPubMedPubMedCentral Chou J, Lin YC, Kim J, You L, Xu Z, He B, Jablons DM: Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck. 2008, 30: 946-963. 10.1002/hed.20833.CrossRefPubMedPubMedCentral
42.
go back to reference Lee KS, Song S, Erikson RL: The polo-box-dependent induction of ectopic septal structures by a mammalian polo kinase, plk, in Saccharomyces cerevisiae. Proc Natl Acad Sci USA. 1999, 96: 14360-14365. 10.1073/pnas.96.25.14360.CrossRefPubMedPubMedCentral Lee KS, Song S, Erikson RL: The polo-box-dependent induction of ectopic septal structures by a mammalian polo kinase, plk, in Saccharomyces cerevisiae. Proc Natl Acad Sci USA. 1999, 96: 14360-14365. 10.1073/pnas.96.25.14360.CrossRefPubMedPubMedCentral
43.
go back to reference He J, Xu J, Xu XX, Hall RA: Cell cycle-dependent phosphorylation of Disabled-2 by cdc2. Oncogene. 2003, 22: 4524-4530. 10.1038/sj.onc.1206767.CrossRefPubMed He J, Xu J, Xu XX, Hall RA: Cell cycle-dependent phosphorylation of Disabled-2 by cdc2. Oncogene. 2003, 22: 4524-4530. 10.1038/sj.onc.1206767.CrossRefPubMed
Metadata
Title
Putative tumour-suppressor gene DAB2is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma
Authors
Joanna H Tong
David C Ng
Shuk L Chau
Ken K So
Patrick P Leung
Tin L Lee
Raymond W Lung
Michael W Chan
Anthony W Chan
Kwok W Lo
Ka F To
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-253

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine